Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Exp Clin Transplant ; 10(1): 76-80, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22309426

ABSTRACT

We report a case of autoimmune polyglandular syndrome type II that developed in an 11-year-old boy with homozygous sickle cell disease after allogeneic bone marrow transplant; the donor was his father, who was human leukocyte antigen identical and had vitiligo. On day 24 after transplant, the patient developed grade 1 acute graft-versus-host disease, which was controlled over a period of 3 months with corticosteroid-induced immunosuppression. Full donor engraftment was documented on day 31 after transplant, and this was further confirmed on days 59, 231, 321, 472, 549, and 720. Three months after transplant, the recipient developed adrenal insufficiency, and at 13 months, he developed vitiligo. Seventeen months after transplant, autoimmune thyroid disease, positive for thyroid peroxidase and thyroglobulin autoantibodies, was diagnosed. At the same time, we identified adrenal insufficiency in the donor. We analyzed a serum sample from the recipient for autoantibody markers for type 1 autoimmune diabetes mellitus. The sample was positive for antiglutamic acid decarboxylase. Antibody against 21-hydroxylase enzyme was also found (261 U/mL; normal value, < 1 U/mL). We conclude that the recipient developed autoimmune polyglandular syndrome type II after bone marrow transplant from his father, who was probably affected by the same syndrome.


Subject(s)
Anemia, Sickle Cell/surgery , Bone Marrow Transplantation/adverse effects , Polyendocrinopathies, Autoimmune/etiology , Polyendocrinopathies, Autoimmune/genetics , Addison Disease/genetics , Adrenal Insufficiency/genetics , Child , Genetic Predisposition to Disease/genetics , Humans , Male , Polyendocrinopathies, Autoimmune/diagnosis , Tissue Donors , Vitiligo/genetics
2.
Exp Clin Transplant ; 8(3): 269-71, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20716049

ABSTRACT

In this article, we report a switch of beta-thalassemia major to intermedia beta-thalassemia after allogeneic bone marrow transplant of a 6-year-old girl from her HLA-matched brother. After stable mixed chimerism, the patient had a secondary graft rejection and returned to total recipient chimerism as assessed by real-time polymerase chain reaction assay. Nonetheless, with a medium hemoglobin rate of 89 g/L, she did not need further transfusions for 60 months after rejection. We conclude that complete loss of donor cells after bone marrow transplant for beta-thalassemia major is compatible with a stable clinical state, probably due to a gamma-globin gene demethylation that enhances gamma-globin chain production and further allows constitution of a fetal hemoglobin rate compatible with free transfusion survival.


Subject(s)
Bone Marrow Transplantation/adverse effects , Graft Rejection/etiology , Transplantation Chimera , beta-Thalassemia/surgery , Child , Family , Female , Fetal Hemoglobin/metabolism , Graft Rejection/blood , Graft Rejection/genetics , Graft Rejection/immunology , HLA Antigens/immunology , Hemoglobin A/metabolism , Hemoglobin A2/metabolism , Histocompatibility Testing , Humans , Polymerase Chain Reaction , Time Factors , Transplantation Chimera/genetics , Transplantation Conditioning , Transplantation, Homologous , Treatment Outcome , beta-Thalassemia/blood , beta-Thalassemia/genetics , beta-Thalassemia/immunology
3.
Pediatr Transplant ; 13(1): 119-22, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18208435

ABSTRACT

T1D after BMT constitutes a human model of autoimmune disease transmission. This case report refers to T1D onset after allogeneic HLA-matched BMT in a six-yr-old recipient affected by aplastic anemia. The donor was his sister who had T1D. The recipient had a complication free course apart from grade 1 acute GVHD, which was resolved spontaneously. With the predictive value and significance of T1D-associated autoantibodies, we tried to consolidate the T1D transfer possibility based on our patient characteristics and a literature review.


Subject(s)
Bone Marrow Transplantation/immunology , Diabetes Mellitus, Type 1/immunology , Anemia, Aplastic/surgery , Autoantibodies/analysis , Child , Graft vs Host Disease/epidemiology , Humans , Male , Tissue Donors
4.
Pediatr Transplant ; 13(8): 1058-61, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19032413

ABSTRACT

Among the cases yet published of development of vitiligo after BMT, only two can claim as possible adoptive transfer of such disease. We report a case of a patient with sickle cell disease in whom vitiligo developed after allogeneic BMT from his HLA identical father affected by vitiligo. We reviewed and searched for some particularities in the reported cases of post-BMT vitiligo.


Subject(s)
Bone Marrow Transplantation/adverse effects , Vitiligo/etiology , Bone Marrow Transplantation/immunology , Child , Graft vs Host Disease/immunology , Humans , Immunosuppression Therapy/methods , Male , Vitiligo/immunology
5.
Pediatr Transplant ; 11(8): 922-6, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17976129

ABSTRACT

OS is a non-SCID immunodeficiency characterized by a poor outcome even after BMT. We report here a case of BMT without preparative conditioning regimen, and with a successful engraftment in a five-month-old infant with OS. The patient was transplanted with 15 x 10(8) bone marrow mononuclear cells/kg, from his HLA matched brother, without preparative regimen and GVHD prophylaxis. Immunological status was assessed before and after the BMT, and the engraftment was monitored with microchimerism analysis. Six days after BMT, an acute GVHD involving first the skin, then the liver and gut, complicated the post-transplantation course. An excellent engraftment was confirmed by donor chimerism over 95% respectively at day post-transplantation 30, 60, 90, and 150. The cellular immunity of the patient was restored, and infectious complications decreased after BMT. Later the patient experienced chronic GVHD, and he died on day post-transplantation 246 from GVHD. BMT without conditioning regimen for OS is feasible, but there must be a megadose cell transplantation, and appropriate prophylactic immunosuppressive treatment to prevent acute GVHD.


Subject(s)
Bone Marrow Transplantation/methods , Graft vs Host Disease/etiology , Severe Combined Immunodeficiency/surgery , Transplantation Conditioning/methods , Fatal Outcome , Follow-Up Studies , Graft vs Host Disease/immunology , Graft vs Host Disease/prevention & control , Humans , Immunity, Cellular , Immunosuppressive Agents/therapeutic use , Infant , Male , Severe Combined Immunodeficiency/immunology , Severity of Illness Index , Syndrome
6.
Ann Pathol ; 23(2): 149-52, 2003 Apr.
Article in French | MEDLINE | ID: mdl-12843969

ABSTRACT

We report a case of nasal NK/T lymphoma occurring in a 42 year old man, after a 2 year history of nasal obstruction initially related to chronic sinusitis. A first superficial biopsy was not contributive. Twenty months later, a second nasal biopsy led to the diagnosis of nasal NK/T cell lymphoma in view of the presence of a pleomorphic lymphoid infiltrate associated with necrosis and angiocentric features. Extensive immunohistochemical studies performed on paraffin and frozen sections together with genotypic analysis supported the NK cell origin of the neoplastic cells. In addition, EBV infection was established by in situ hybridization which showed EBERs transcripts in the nuclei of virtually all neoplastic cells. The tumour rapidly progressed and the patient died six months after diagnosis.


Subject(s)
Killer Cells, Natural/pathology , Lymphoma, T-Cell/pathology , Nose Neoplasms/pathology , Adult , Biopsy , Epstein-Barr Virus Infections/diagnosis , Genotype , Humans , Immunohistochemistry , Immunophenotyping , Lymphoma, T-Cell/genetics , Lymphoma, T-Cell/microbiology , Male , Nasal Obstruction/etiology , Nose Neoplasms/chemistry , Nose Neoplasms/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...